Toll-like receptors in the pathogenesis of autoimmune diseases: recent and emerging translational developments

Interleukin-6, its role in fibrosing conditions

Bioengineering the microanatomy of human skin

Interleukin‐6: a new therapeutic target in systemic sclerosis?

Epigenetics in fibrosis

MiR-29a reduces TIMP-1 production by dermal fibroblasts via targeting TGF-β activated kinase 1 binding protein 1, implications for systemic sclerosis

IL-13 mediates collagen deposition via STAT6 and microRNA-135b: a role for epigenetics

Role of innate immune system in systemic sclerosis

Role of interleukin‐13 in fibrosis, particularly systemic sclerosis

Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors

Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential

Serum amyloid A induces interleukin‐6 in dermal fibroblasts via Toll‐like receptor 2, interleukin‐1 receptor‐associated kinase 4 and nuclear factor‐κB

Tumor necrosis factor–costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts

Innate immunity in systemic sclerosis

Inducers of cross-linked actin networks in trabecular meshwork cells

Differentiation potential of CD14+ monocytes into myofibroblasts in patients with systemic sclerosis

Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and …

T cells in systemic sclerosis: a reappraisal

MicroRNAs in fibrosis: opportunities and challenges

The immunopathogenesis of fibrosis in systemic sclerosis